Consulting Services
For Investors
Products
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News

Contact Us

Search

Etomidate

Cardiovascular

Cardiovascular Today—December 18, 2025

This week’s cardiovascular update brings together the latest trial results,…

Cardiovascular

Cardiovascular Today—December 10, 2025

This week’s cardiovascular update brings together new clinical evidence, device…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Oncology Today—February 2, 2026
Hematology Today—February 2, 2026
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration

Tags

advanced therapies amylin analog Antengene bioinformatics blood test cancer Cardiovascular market trends Central nervous system diseases Chronic disease management ckd CONMED corporate venture capital drug pricing drug supply chain Elranatamab ESMO 2021 gene editing gene therapy approval Harbour BioMed Health systems innovation hematology Hormone therapy development Human Metapneumovirus investment Mass General Brigham Minaris Regenerative Medicine MSRD nanotechnology NFTs in healthcare non-dilutive funding non viral vectors oncology trials Opna Bio oral GLP-1 therapies PD-1 combinations pharma Pulmonary disease treatments remote patient monitoring Salk Institute scientific computing Sema4 tissue engineering unconventional trial designs vector-borne disease Zevra Therapeutics

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Oncology Today—February 2, 2026
Hematology Today—February 2, 2026
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration

TAGS

advanced therapies amylin analog Antengene bioinformatics blood test cancer Cardiovascular market trends Central nervous system diseases Chronic disease management ckd CONMED corporate venture capital drug pricing drug supply chain Elranatamab ESMO 2021 gene editing gene therapy approval Harbour BioMed Health systems innovation hematology Hormone therapy development Human Metapneumovirus investment Mass General Brigham Minaris Regenerative Medicine MSRD nanotechnology NFTs in healthcare non-dilutive funding non viral vectors oncology trials Opna Bio oral GLP-1 therapies PD-1 combinations pharma Pulmonary disease treatments remote patient monitoring Salk Institute scientific computing Sema4 tissue engineering unconventional trial designs vector-borne disease Zevra Therapeutics

Consulting Services
For Investors
Products
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy